Cargando…
Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice
HER-2/neu is a tumour antigen that is overexpressed in human breast tumours. Among the vaccine strategies developed to overcome immune tolerance to self-proteins, vaccination with anti-idiotypic (anti-Id) antibodies has been described as a promising approach for treatment of several malignant diseas...
Autores principales: | Coelho, M, Gauthier, P, Pugnière, M, Roquet, F, Pèlegrin, A, Navarro-Teulon, I |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409470/ https://www.ncbi.nlm.nih.gov/pubmed/15138490 http://dx.doi.org/10.1038/sj.bjc.6601825 |
Ejemplares similares
-
Potential of an anti-bevacizumab idiotype scFv DNA-based immunization to elicit VEGF-binding antibody response
por: Silva, Tábata Almeida, et al.
Publicado: (2022) -
Anti-Idiotype scFv Localizes an Autoepitope in the Globular Domain of C1q
por: Todorova, Nadezhda, et al.
Publicado: (2021) -
Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice
por: Ladjemi, Maha Z, et al.
Publicado: (2011) -
Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes
por: Marty, C, et al.
Publicado: (2002) -
A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug
por: de Graaf, M, et al.
Publicado: (2002)